- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
This protein engineering firm claims its therapies, modeled on the naturally secreted human serum protein tetranectin, could compete with antibodies. Access through your institution Buy or
subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online
access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which
are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support AUTHOR INFORMATION AUTHORS AND
AFFILIATIONS * London Jennifer Rohn Authors * Jennifer Rohn View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and
permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Rohn, J. Newsmaker: Anaphore. _Nat Biotechnol_ 28, 1143 (2010). https://doi.org/10.1038/nbt1110-1143 Download citation * Published: 05
November 2010 * Issue Date: November 2010 * DOI: https://doi.org/10.1038/nbt1110-1143 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get
shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative
